查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2094839

醫療設備非臨床試驗服務市場－2026-2032年全球市場預測

Preclinical Medical Device Testing Services Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，醫療設備非臨床試驗服務市場規模將成長至 76.9 億美元，複合年成長率為 10.33%。

主要市場統計數據
基準年 2025 38.6億美元
預計年份：2026年 42.5億美元
預測年份 2032 76.9億美元
複合年成長率 (%) 10.33%

臨床前醫療設備測試服務對於在首次人體試驗或提交監管申請之前，驗證醫療器材的安全性、性能、生物相容性、電氣安全性、機械完整性、易用性和生物風險管理至關重要。此領域涵蓋多種醫療設備、診斷器械、藥研一體醫療設備、手術器械、穿戴式技術、互聯醫療設備和軟體系統。醫療設備醫療設備設計日益複雜、監管要求日益嚴格、全球協調努力不斷推進，以及需要提供符合相關認證標準的可靠證據（例如，用於生物評估的 ISO 10993、用於風險管理的 ISO 14971、用於醫用電氣設備的 IEC 60601、用於醫療設備設備的 IEC 60601、用於醫療器械軟體的 IEC 62304、用於醫療設備的 IEC 60601、用於醫療器械軟體的 IEC 62304、用於用於滅菌工程的 IEC 60636、 11135 和 ISO 11137，以及在適用情況下，良好實驗室規範 (GLP) 原則），這些因素共同推動了市場需求的成長。

經營團隊重點正從單純進行試驗轉向以證據為基礎的綜合規劃。製造商越來越需要透過可追溯的、基於風險的方法，提供試驗選擇、材料特性、毒理學風險評估、滅菌驗證、包裝完整性、網路安全考量以及人為因素等方面的證據。隨著監管機構日益重視生命週期安全性和上市後研究結果，臨床前試驗策略的設計必須能夠經受住跨司法管轄區的科學審查，同時減少重複試驗、避免不必要的動物試驗並加快研發進度，所有這些都必須在不損害患者安全的前提下進行。

臨床前試驗領域的變革性變化

醫療設備非臨床測試的格局正因監管趨同、材料創新、數位化以及對器材安全性的日益嚴格監管而重塑。全球監管機構越來越傾向於建立基於風險的證據，而非標準化測試。這一點在生物學評估中尤其明顯，化學表徵、萃取物和洗脫液分析、毒理學風險評估以及基於文獻的論證正被用於在科學合理的情況下最佳化和減少動物試驗。符合「3R原則」（替代、減少、改進）的替代方法日益受到認可，並持續影響實驗室策略和申辦者的預期。

人工智慧在臨床前試驗中的累積影響

人工智慧 (AI) 透過改進試驗設計、證據整合、實驗室工作流程效率和風險檢測，對醫療設備的非臨床試驗整體產生累積的影響。在規劃階段，AI 工具可以輔助進行文獻綜述、標準映射、風險因素識別、材料資訊分析以及對以往申請材料、測試報告和監管指導文件進行差距評估。在適當的人工監督下實施這些功能，有助於團隊確定相關終點、減少重複試驗並加強試驗選擇的科學依據。

醫療設備非臨床試驗的關鍵區域性見解

在亞太地區，隨著中國、日本、韓國、印度、澳洲和東協等市場持續推動國內醫療設備創新，並努力使許多技術要求與國際標準接軌，該地區在臨床前醫療設備測試領域的作用日益凸顯。植入、診斷設備、數位醫療設備和醫院設備的產量不斷成長，導致對生物相容性測試、電氣安全測試、無菌保證、軟體相關檢驗數據和性能檢驗的需求日益增加。由於監管路徑仍然存在差異，因此在文件編制、樣品要求、本地測試預期以及海外測試數據的認可等方面，本地專業知識至關重要。

領先的集團對全球醫療設備測試生態系統的洞察

北約成員國認為，醫療設備在與國防醫療系統、急診醫學、創傷護理、現場診斷、復健以及採購標準相關的領域至關重要，這些領域要求醫療器材具備互通性、穩健性和經認證的安全性能。七國集團共同建構了一個成熟的醫療技術環境，其監管機構、標準化機構和醫療保健系統高度重視證據品質、病人安全、網路安全、生命週期監測、人因工程以及科學合理的臨床前試驗。

各國對醫療設備非臨床試驗的深入了解

在美國，醫療器材監管高度重視基於風險的證據、廣泛認可的共識標準、設計控制、軟體考量、網路安全、人為因素、無菌保證和生物評估。加拿大擁有系統化的醫療設備許可框架，其中安全性、有效性、品質系統狀況以及符合國際標準均被視為重要考量。墨西哥的醫療設備環境受到監管現代化、進口監控以及對符合合規要求的文件的需求的影響，這些文件對於獲得醫療機構的准入至關重要。在巴西，必須格外注意醫療設備分類、當地監管要求、品質系統證據和技術文檔，並且在向監管機構提交申請時，確保臨床前試驗符合監管要求至關重要。

為行業領導者提供的實用建議

產業領導者應從設計初期就開始規劃臨床前試驗，並將所有試驗與醫療設備風險管理文件關聯起來。生物評估計劃應優先考慮材料表徵、化學分析、毒理學風險評估以及科學合理的終點選擇。機械、電氣、軟體、滅菌、包裝和可用性測試應協調進行，以避免因測試順序、證據不一致、測試理由不足以及後期糾正措施而導致的延誤。

調查方法

本執行摘要採用系統的二手資料研究方法編寫，所用資料均為公開權威的資源，包括醫療設備監管資訊來源、國際標準參考資料、公共衛生機構資料、標準化機構出版刊物、同行評審的科學文獻以及生物學評估、風險管理、檢查室質量和醫療設備安全方面的認可調查方法。本分析著重於檢驗的監管和技術趨勢，而非市場規模、市場佔有率或預測。

結論

醫療設備的非臨床測試服務正從單純的合約測試轉向產生綜合性的、基於風險的證據。最成功的項目將測試與器械設計、預期用途、材料成分、患者接觸、軟體功能、滅菌方法、包裝配置、人因工程以及相關司法管轄區的監管要求相結合。隨著技術日益複雜，全球申報要求也日益嚴格，提供科學合理、可追溯且符合審計要求的非臨床證據的能力正成為一項策略優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：醫療設備非臨床試驗服務市場：依服務類型分類

  • 體內試驗
    • 生物相容性和毒性測試
    • 植入性能和耐久性
    • 藥物動力學和生物分佈
    • 安全性和耐受性測試
  • 體外試驗
    • 基於細胞的檢測
    • 血液相容性測試
    • 遺傳毒性和細胞毒性測試
  • 台式試驗和機械試驗
    • 性能和功能測試
    • 生理和環境壓力測試
  • 微生物學和無菌檢測服務
    • 無菌保證和驗證
    • 微生物限量和微生物附著量測試
    • 抗菌功效測試
  • 包裝及保鮮服務
    • 包裝完整性測試
    • 運輸和配送模擬
    • 加速老化和即時老化測試
  • 軟體和數位健康試驗
    • 內建軟體檢驗
    • 網路安全和連接性測試
    • 人因工程與可用性工程
  • 化學表徵服務
    • 萃取和洗脫試驗
    • 材料性能評價
    • 殘留物和污染物分析

第8章：醫療設備非臨床試驗服務市場：依醫療設備類別分類

  • 植入式醫療設備
    • 心血管植入
    • 整形外科植入
    • 植入
    • 眼科植入
    • 神經調節植入
  • 非植入式醫療設備
    • 手術器械
    • 用於創傷護理的醫療設備
    • 診斷和監測設備
    • 穿戴式醫療設備
    • 免洗拋棄式產品
  • 體外診斷醫療設備
    • 試劑組和檢測
    • 儀器/分析儀
    • 即時檢測（POC​​）體外診斷設備

第9章：醫療設備非臨床試驗服務市場：外包模式

  • 全方位外包
  • 職能外包
  • 企劃為基礎合約
  • 長期策略夥伴關係
  • 內部資源支持

第10章：醫療設備非臨床試驗服務市場：以動物模型類型分類

  • 囓齒動物
  • 兔子
  • 狗
  • 豬
  • 非人靈長類動物

第11章：醫療設備非臨床試驗服務市場：依應用領域分類

  • 醫療設備安全評價
  • 有效性和性能測試
  • 原型檢驗
  • 支持向監管機構（FDA/HC）提交申請

第12章：醫療設備非臨床試驗服務市場：依最終用戶分類

  • 醫療設備製造商
  • 合約研發生產組織（CDMO）
  • 學術和研究機構
    • 大學及教學醫院
    • 獨立研究機構
  • 政府和非營利組織
    • 公共衛生組織
    • 標準化和監管機構
  • 投資者和策略夥伴
    • 創業投資與私募股權
    • 策略企業投資者

第13章：醫療設備非臨床試驗服務市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章：醫療設備非臨床試驗服務市場：依類別分類

  • NATO
  • G7
  • EU
  • BRICS
  • ASEAN
  • GCC

第15章：醫療設備非臨床試驗服務市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 日本
  • 印度
  • 英國
  • 法國
  • 加拿大
  • 義大利
  • 澳洲
  • 韓國
  • 巴西
  • 墨西哥
  • 俄羅斯
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AGINKO Research AG
  • Bureau Veritas SA
  • Canyon Labs
  • CERTANIA Holding GmbH
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific SE
  • Gradient, Inc.
  • ICON plc
  • Inotiv, Inc.
  • Intertek Group plc
  • IQVIA Holdings Inc.
  • Laboratory Corporation of America Holdings
  • Lahav CRO Ltd.
  • Medistri SA
  • Medpace Holdings, Inc.
  • NAMSA, Inc.
  • Pace Analytical Services, LLC
  • Parexel International（MA）Corporation
  • Pharmaron（Beijing）Co., Ltd.
  • Porsolt SAS
  • RQM+, Inc.
  • SGS SA
  • STEMart
  • Sterigenics International LLC
  • TUV SUD AG
  • UL LLC
  • Veeda Lifesciences
  • Veranex, LLC
  • WuXi AppTec Co., Ltd.
Product Code: MRR-3A2E844FD678

The Preclinical Medical Device Testing Services Market is projected to grow by USD 7.69 billion at a CAGR of 10.33% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.86 billion
Estimated Year [2026] USD 4.25 billion
Forecast Year [2032] USD 7.69 billion
CAGR (%) 10.33%

Preclinical medical device testing services are essential to demonstrating safety, performance, biocompatibility, electrical safety, mechanical integrity, usability, and biological risk control before first-in-human use or regulatory submission. The sector supports a wide range of devices, including implantable devices, diagnostic equipment, drug-device combinations, surgical instruments, wearable technologies, connected medical devices, and software-enabled systems. Demand is shaped by increasingly complex device designs, stricter regulatory expectations, global harmonization efforts, and the need to generate reliable evidence aligned with recognized standards such as ISO 10993 for biological evaluation, ISO 14971 for risk management, IEC 60601 for electrical medical equipment, IEC 62304 for medical device software, IEC 62366 for usability engineering, ISO 11607 for packaging, ISO 11135 and ISO 11137 for sterilization, and good laboratory practice principles where applicable.

The executive priority is shifting from test execution alone to integrated evidence planning. Manufacturers are increasingly expected to justify test selection, material characterization, toxicological risk assessment, sterilization validation, packaging integrity, cybersecurity considerations, and human factors evidence through a traceable risk-based approach. As regulatory bodies emphasize lifecycle safety and postmarket learning, preclinical testing strategies must be designed to withstand scientific review across jurisdictions while reducing redundant testing, avoiding unnecessary animal use, and accelerating development timelines without compromising patient safety.

Transformative Shifts in the Preclinical Testing Landscape

The preclinical medical device testing landscape is being reshaped by regulatory convergence, materials innovation, digitalization, and rising scrutiny of device safety. Global regulators increasingly encourage risk-based evidence generation rather than one-size-fits-all testing. This is particularly visible in biological evaluation, where chemical characterization, extractables and leachables analysis, toxicological risk assessment, and literature-based justification are being used to refine or reduce animal testing when scientifically valid. The growing acceptance of alternatives aligned with the 3Rs principles-replacement, reduction, and refinement-continues to influence laboratory strategies and sponsor expectations.

Medical devices are also becoming more complex. Additively manufactured implants, resorbable materials, combination products, nanomaterials, wearable sensors, robotic systems, and connected devices require multidisciplinary preclinical programs that combine mechanical testing, biocompatibility, electromagnetic compatibility, software validation inputs, cybersecurity evidence, sterilization assurance, and packaging validation. This has shifted service expectations from isolated testing modules to end-to-end regulatory science support.

Another major shift is the globalization of submissions. Manufacturers seeking access to multiple regions must align preclinical evidence with international standards while accounting for country-specific requirements, local language documentation, and authority-specific expectations. As a result, testing service providers are being evaluated not only on laboratory capacity, but also on technical interpretation, accreditation, audit readiness, quality system maturity, digital data integrity, and the ability to support regulatory traceability across the device lifecycle.

Cumulative Impact of Artificial Intelligence on Preclinical Testing

Artificial intelligence is exerting a cumulative impact across preclinical medical device testing by improving study design, evidence synthesis, laboratory workflow efficiency, and risk detection. In the planning phase, AI-enabled tools can assist with literature surveillance, standards mapping, hazard identification, materials intelligence, and gap assessment across prior submissions, test reports, and regulatory guidance documents. When deployed with appropriate human oversight, these capabilities help teams identify relevant endpoints, reduce duplicative testing, and strengthen the scientific rationale behind test selection.

In laboratory operations, AI and machine learning are increasingly relevant to imaging analysis, biomechanical signal interpretation, anomaly detection, quality control trending, and automated data review. For connected and software-enabled medical devices, AI can also support simulation-driven verification, model-based analysis, and large-scale review of device performance datasets. However, its use requires strong governance. Data provenance, model validation, bias management, cybersecurity, audit trails, and explainability are critical because preclinical evidence must be reproducible, reviewable, and scientifically defensible.

The most important near-term value of AI is not replacing regulatory judgment, but improving consistency and speed in evidence generation. Industry leaders are using AI to connect risk management files, biological evaluation plans, design verification activities, and test outcomes into more coherent evidence packages. This supports faster identification of safety signals, more efficient documentation, and better alignment between engineering decisions and regulatory expectations.

Key Regional Insights for Preclinical Medical Device Testing

Asia-Pacific is strengthening its role in preclinical medical device testing as China, Japan, South Korea, India, Australia, and ASEAN markets expand domestic device innovation while aligning many technical requirements with international standards. The region shows strong demand for biocompatibility testing, electrical safety testing, sterility assurance, software-related verification inputs, and performance validation due to rising production of implants, diagnostics, digital health devices, and hospital equipment. Regulatory pathways remain diverse, making local expertise important for documentation, sample requirements, local testing expectations, and acceptance of overseas test data.

Europe continues to require rigorous clinical and preclinical evidence under a demanding regulatory framework, with strong focus on technical documentation, biological safety, postmarket linkage, risk management, and conformity assessment. The European regulatory environment has increased the importance of well-structured biological evaluation reports, performance evidence, sterilization validation, packaging validation, usability engineering, software documentation, and traceable design verification. North America remains a highly influential region due to mature regulatory expectations, strong adoption of risk-based testing, and extensive development activity in implantables, cardiovascular devices, orthopedics, diagnostics, digital devices, and combination technologies. Evidence packages in this region commonly emphasize traceability between risk management, design verification, biological evaluation, software considerations, cybersecurity, sterilization, and usability engineering.

Latin America presents a mixed regulatory environment where Brazil and Mexico are important access points for medical device approvals and quality system compliance. Demand is supported by modernization of healthcare systems, increased import regulation, and growing local distribution of advanced devices. Africa is gradually expanding regulatory capacity through regional harmonization initiatives, with preclinical testing needs often linked to imported device approvals, public health procurement, diagnostics, and essential medical technologies. The Middle East is advancing medical infrastructure and regulatory oversight, particularly in countries investing in healthcare modernization, domestic life sciences capabilities, hospital expansion, and digital health adoption, which supports demand for documented safety, performance, sterility, and electrical safety evidence.

Key Group Insights Across Global Device Testing Ecosystems

NATO countries are relevant where medical devices intersect with defense health systems, emergency care, trauma medicine, field diagnostics, rehabilitation, and procurement standards requiring reliability, interoperability, ruggedization, and documented safety performance. G7 countries collectively represent mature medical technology environments where regulators, standards bodies, and healthcare systems place strong emphasis on evidence quality, patient safety, cybersecurity, lifecycle surveillance, human factors, and scientifically justified preclinical testing.

The European Union requires comprehensive technical documentation under a stringent regulatory environment, making robust preclinical evidence central to device conformity. Biological evaluation, performance testing, sterilization validation, software documentation, usability, packaging integrity, and risk management must be integrated into a defensible lifecycle file. BRICS countries represent a diverse set of regulatory systems with growing domestic manufacturing, expanding healthcare access, and increased scrutiny of safety and performance evidence. China, India, Brazil, Russia, and South Africa each present distinct documentation and testing expectations, making harmonized test strategies valuable but not always sufficient without local adaptation.

ASEAN countries are becoming more relevant for preclinical medical device testing as regional regulatory alignment efforts support greater consistency in classification, technical documentation, and conformity assessment principles. While implementation varies by country, manufacturers targeting ASEAN markets benefit from preclinical packages built around internationally recognized standards and adaptable to local registration requirements. The GCC region is increasing its reliance on structured device registration, quality documentation, and conformity evidence as healthcare investment rises across Gulf economies. Preclinical testing demand is closely linked to imported medical technologies, hospital modernization, and the introduction of advanced diagnostics, surgical equipment, connected devices, and digital care infrastructure.

Key Country Insights for Preclinical Medical Device Testing

The United States places strong emphasis on risk-based evidence, recognized consensus standards, design controls, software considerations, cybersecurity, human factors, sterility assurance, and biological evaluation. Canada maintains a structured medical device licensing framework where safety, effectiveness, quality system readiness, and international standard alignment are important. Mexico's device environment is shaped by regulatory modernization, import oversight, and demand for compliant documentation supporting access to healthcare institutions. Brazil requires careful attention to device classification, local regulatory expectations, quality system evidence, and technical documentation, making preclinical testing alignment important for regulatory submissions.

China has a sophisticated and increasingly innovation-oriented medical device regulatory system, with local testing and registration expectations often influencing preclinical strategy. India is expanding regulation across more device categories, increasing the importance of documented safety, performance, and quality evidence. Japan maintains rigorous expectations for device safety and performance, particularly for advanced and high-risk technologies, and often requires careful alignment with local regulatory processes. Australia uses a risk-based regulatory framework linked to recognized evidence and conformity assessment principles. South Korea combines strong domestic medtech innovation with detailed regulatory review, supporting demand for high-quality preclinical testing in implants, diagnostics, digital devices, and electronic medical equipment.

The United Kingdom continues to maintain an active medical device oversight framework with evolving post-Brexit regulatory requirements, while Germany, France, Italy, and Spain operate within the European regulatory environment that prioritizes conformity assessment, technical documentation, clinical evaluation linkage, and robust preclinical evidence. Italy and Spain also reflect strong demand for compliant documentation supporting hospital procurement, imported devices, and specialty care technologies. Russia applies national registration expectations requiring attention to local testing, documentation, and conformity procedures. Across these countries, device makers must maintain traceable evidence across risk management, materials characterization, mechanical performance, usability, sterilization, packaging, electrical safety, software, and postmarket planning.

Actionable Recommendations for Industry Leaders

Industry leaders should begin preclinical planning at the earliest design stage and connect every study to the device risk management file. Biological evaluation plans should prioritize material characterization, chemical analysis, toxicological risk assessment, and scientifically justified endpoint selection. Mechanical, electrical, software, sterilization, packaging, and usability testing should be coordinated to avoid sequencing delays, conflicting evidence, incomplete test rationales, and late-stage remediation.

Manufacturers should build global submission strategies around recognized standards while identifying local regulatory deviations early. Testing partners should be assessed for accreditation status, quality system maturity, audit history, data integrity controls, method validation capability, scientific expertise, sample handling processes, and experience with the target device category. For innovative devices, sponsors should engage in early regulatory dialogue where available and document rationales for novel methods, simulations, alternative models, or reduced animal testing.

Digital transformation should be adopted with governance. AI-enabled evidence review, laboratory automation, and data analytics can improve speed and consistency, but outputs must remain transparent, validated, and reviewable. Leaders should also strengthen cybersecurity-by-design, sustainability in test planning, supplier traceability, and change control, especially for devices using complex materials, electronics, software, sterilization-sensitive components, or global manufacturing networks.

Research Methodology

This executive summary is developed through a structured secondary research methodology using publicly available and authoritative sources, including medical device regulatory guidance, international standards references, public health agency materials, standards organization publications, peer-reviewed scientific literature, and recognized frameworks for biological evaluation, risk management, laboratory quality, and device safety. The analysis focuses on verified regulatory and technical trends rather than market sizing, market share, or forecasting.

The research approach includes cross-checking regional and country-level regulatory developments, mapping preclinical testing requirements to recognized standards, reviewing scientific shifts in biocompatibility and toxicological risk assessment, and evaluating the implications of digital health, connected devices, artificial intelligence, and alternative testing methods. Insights are synthesized to support strategic decision-making for manufacturers, testing laboratories, regulatory teams, product developers, and quality leaders involved in preclinical medical device testing services.

Conclusion

Preclinical medical device testing services are moving from transactional laboratory execution toward integrated, risk-based evidence generation. The most successful programs align testing with device design, intended use, material composition, patient contact, software functionality, sterilization method, packaging configuration, human factors, and jurisdiction-specific regulatory expectations. As technologies become more complex and global submissions become more demanding, the ability to produce scientifically defensible, traceable, and audit-ready preclinical evidence is becoming a strategic advantage.

Artificial intelligence, alternative testing approaches, advanced material characterization, and digital quality systems will continue to improve efficiency, but regulatory acceptance depends on transparency, validation, and scientific rigor. Industry leaders that invest early in evidence planning, global standards alignment, and high-integrity data practices will be better positioned to reduce development risk, support regulatory review, and deliver safer medical devices to patients and healthcare systems worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Preclinical Medical Device Testing Services Market, by Service Type

  • 7.1. Introduction
  • 7.2. In Vivo Testing
    • 7.2.1. Biocompatibility & Toxicology Studies
    • 7.2.2. Implant Performance & Durability
    • 7.2.3. Pharmacokinetics & Biodistribution
    • 7.2.4. Safety & Tolerability Studies
  • 7.3. In Vitro Testing
    • 7.3.1. Cell-Based Assays
    • 7.3.2. Hemocompatibility Testing
    • 7.3.3. Genotoxicity & Cytotoxicity Testing
  • 7.4. Bench & Mechanical Testing
    • 7.4.1. Performance & Functional Testing
    • 7.4.2. Physical & Environmental Stress Testing
  • 7.5. Microbiology & Sterility Services
    • 7.5.1. Sterility Assurance & Validation
    • 7.5.2. Microbial Limits & Bioburden Testing
    • 7.5.3. Antimicrobial Efficacy Testing
  • 7.6. Packaging & Shelf-Life Services
    • 7.6.1. Package Integrity Testing
    • 7.6.2. Transportation & Distribution Simulation
    • 7.6.3. Accelerated & Real-Time Aging Studies
  • 7.7. Software & Digital Health Testing
    • 7.7.1. Embedded Software Verification
    • 7.7.2. Cybersecurity & Connectivity Testing
    • 7.7.3. Human Factors & Usability Engineering
  • 7.8. Chemical Characterization Services
    • 7.8.1. Extractables & Leachables Studies
    • 7.8.2. Material Characterization
    • 7.8.3. Residuals & Contaminants Analysis

8. Preclinical Medical Device Testing Services Market, by Device Category

  • 8.1. Introduction
  • 8.2. Implantable Devices
    • 8.2.1. Cardiovascular Implants
    • 8.2.2. Orthopedic Implants
    • 8.2.3. Dental Implants
    • 8.2.4. Ophthalmic Implants
    • 8.2.5. Neuromodulation Implants
  • 8.3. Non Implantable Devices
    • 8.3.1. Surgical Instruments
    • 8.3.2. Wound Care Devices
    • 8.3.3. Diagnostic & Monitoring Equipment
    • 8.3.4. Wearable Medical Devices
    • 8.3.5. Single Use Disposables
  • 8.4. In Vitro Diagnostic Devices
    • 8.4.1. Reagent Kits & Assays
    • 8.4.2. Instruments & Analyzers
    • 8.4.3. Point Of Care IVD Devices

9. Preclinical Medical Device Testing Services Market, by Outsourcing Model

  • 9.1. Introduction
  • 9.2. Full-Service Outsourcing
  • 9.3. Functional Outsourcing
  • 9.4. Project-Based Engagements
  • 9.5. Long-Term Strategic Partnerships
  • 9.6. Insourcing Support

10. Preclinical Medical Device Testing Services Market, by Animal Model Type

  • 10.1. Introduction
  • 10.2. Rodents
  • 10.3. Rabbits
  • 10.4. Canines
  • 10.5. Swine
  • 10.6. Non-Human Primates

11. Preclinical Medical Device Testing Services Market, by Application

  • 11.1. Introduction
  • 11.2. Device Safety Assessment
  • 11.3. Efficacy & Performance Studies
  • 11.4. Prototype Validation
  • 11.5. Regulatory Submission Support (FDA/HC)

12. Preclinical Medical Device Testing Services Market, by End-User

  • 12.1. Introduction
  • 12.2. Medical Device Manufacturers
  • 12.3. Contract Development & Manufacturing Organizations
  • 12.4. Academic & Research Institutions
    • 12.4.1. Universities & Teaching Hospitals
    • 12.4.2. Independent Research Institutes
  • 12.5. Government & Nonprofit Organizations
    • 12.5.1. Public Health Agencies
    • 12.5.2. Standards & Regulatory Bodies
  • 12.6. Investors & Strategic Partners
    • 12.6.1. Venture Capital & Private Equity
    • 12.6.2. Strategic Corporate Investors

13. Preclinical Medical Device Testing Services Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Preclinical Medical Device Testing Services Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. ASEAN
  • 14.6. GCC

15. Preclinical Medical Device Testing Services Market, by Country

  • 15.1. United States
  • 15.2. China
  • 15.3. Germany
  • 15.4. Japan
  • 15.5. India
  • 15.6. United Kingdom
  • 15.7. France
  • 15.8. Canada
  • 15.9. Italy
  • 15.10. Australia
  • 15.11. South Korea
  • 15.12. Brazil
  • 15.13. Mexico
  • 15.14. Russia
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AGINKO Research AG
  • 17.2. Bureau Veritas S.A.
  • 17.3. Canyon Labs
  • 17.4. CERTANIA Holding GmbH
  • 17.5. Charles River Laboratories International, Inc.
  • 17.6. Eurofins Scientific SE
  • 17.7. Gradient, Inc.
  • 17.8. ICON plc
  • 17.9. Inotiv, Inc.
  • 17.10. Intertek Group plc
  • 17.11. IQVIA Holdings Inc.
  • 17.12. Laboratory Corporation of America Holdings
  • 17.13. Lahav CRO Ltd.
  • 17.14. Medistri SA
  • 17.15. Medpace Holdings, Inc.
  • 17.16. NAMSA, Inc.
  • 17.17. Pace Analytical Services, LLC
  • 17.18. Parexel International (MA) Corporation
  • 17.19. Pharmaron (Beijing) Co., Ltd.
  • 17.20. Porsolt SAS
  • 17.21. RQM+, Inc.
  • 17.22. SGS SA
  • 17.23. STEMart
  • 17.24. Sterigenics International LLC
  • 17.25. TUV SUD AG
  • 17.26. UL LLC
  • 17.27. Veeda Lifesciences
  • 17.28. Veranex, LLC
  • 17.29. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DEVICE CATEGORY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DEVICE CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY OUTSOURCING MODEL, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY OUTSOURCING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ANIMAL MODEL TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ANIMAL MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IN VIVO TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN VIVO TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IN VIVO TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOCOMPATIBILITY & TOXICOLOGY STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOCOMPATIBILITY & TOXICOLOGY STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOCOMPATIBILITY & TOXICOLOGY STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMPLANT PERFORMANCE & DURABILITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMPLANT PERFORMANCE & DURABILITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMPLANT PERFORMANCE & DURABILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOKINETICS & BIODISTRIBUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOKINETICS & BIODISTRIBUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOKINETICS & BIODISTRIBUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SAFETY & TOLERABILITY STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SAFETY & TOLERABILITY STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SAFETY & TOLERABILITY STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN VITRO TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IN VITRO TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IN VITRO TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL-BASED ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL-BASED ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL-BASED ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEMOCOMPATIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEMOCOMPATIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEMOCOMPATIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENOTOXICITY & CYTOTOXICITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENOTOXICITY & CYTOTOXICITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENOTOXICITY & CYTOTOXICITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BENCH & MECHANICAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BENCH & MECHANICAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BENCH & MECHANICAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PERFORMANCE & FUNCTIONAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PERFORMANCE & FUNCTIONAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PERFORMANCE & FUNCTIONAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHYSICAL & ENVIRONMENTAL STRESS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHYSICAL & ENVIRONMENTAL STRESS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHYSICAL & ENVIRONMENTAL STRESS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MICROBIOLOGY & STERILITY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MICROBIOLOGY & STERILITY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MICROBIOLOGY & STERILITY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL STERILITY ASSURANCE & VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL STERILITY ASSURANCE & VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL STERILITY ASSURANCE & VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MICROBIAL LIMITS & BIOBURDEN TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MICROBIAL LIMITS & BIOBURDEN TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MICROBIAL LIMITS & BIOBURDEN TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMICROBIAL EFFICACY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMICROBIAL EFFICACY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMICROBIAL EFFICACY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PACKAGING & SHELF-LIFE SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PACKAGING & SHELF-LIFE SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PACKAGING & SHELF-LIFE SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PACKAGE INTEGRITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PACKAGE INTEGRITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PACKAGE INTEGRITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TRANSPORTATION & DISTRIBUTION SIMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSPORTATION & DISTRIBUTION SIMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TRANSPORTATION & DISTRIBUTION SIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACCELERATED & REAL-TIME AGING STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ACCELERATED & REAL-TIME AGING STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACCELERATED & REAL-TIME AGING STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SOFTWARE & DIGITAL HEALTH TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SOFTWARE & DIGITAL HEALTH TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SOFTWARE & DIGITAL HEALTH TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL EMBEDDED SOFTWARE VERIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EMBEDDED SOFTWARE VERIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL EMBEDDED SOFTWARE VERIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CYBERSECURITY & CONNECTIVITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CYBERSECURITY & CONNECTIVITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CYBERSECURITY & CONNECTIVITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN FACTORS & USABILITY ENGINEERING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN FACTORS & USABILITY ENGINEERING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN FACTORS & USABILITY ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CHEMICAL CHARACTERIZATION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHEMICAL CHARACTERIZATION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CHEMICAL CHARACTERIZATION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL EXTRACTABLES & LEACHABLES STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL EXTRACTABLES & LEACHABLES STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL EXTRACTABLES & LEACHABLES STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MATERIAL CHARACTERIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MATERIAL CHARACTERIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MATERIAL CHARACTERIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RESIDUALS & CONTAMINANTS ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RESIDUALS & CONTAMINANTS ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RESIDUALS & CONTAMINANTS ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMPLANTABLE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMPLANTABLE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMPLANTABLE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CARDIOVASCULAR IMPLANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIOVASCULAR IMPLANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CARDIOVASCULAR IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORTHOPEDIC IMPLANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ORTHOPEDIC IMPLANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORTHOPEDIC IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DENTAL IMPLANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DENTAL IMPLANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DENTAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OPHTHALMIC IMPLANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OPHTHALMIC IMPLANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL OPHTHALMIC IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEUROMODULATION IMPLANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROMODULATION IMPLANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEUROMODULATION IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NON IMPLANTABLE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NON IMPLANTABLE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NON IMPLANTABLE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SURGICAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SURGICAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SURGICAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL WOUND CARE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL WOUND CARE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL WOUND CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL WEARABLE MEDICAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL WEARABLE MEDICAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL WEARABLE MEDICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SINGLE USE DISPOSABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL SINGLE USE DISPOSABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL SINGLE USE DISPOSABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL IN VITRO DIAGNOSTIC DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL IN VITRO DIAGNOSTIC DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL IN VITRO DIAGNOSTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL REAGENT KITS & ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL REAGENT KITS & ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL REAGENT KITS & ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL INSTRUMENTS & ANALYZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL INSTRUMENTS & ANALYZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL INSTRUMENTS & ANALYZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL POINT OF CARE IVD DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL POINT OF CARE IVD DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL POINT OF CARE IVD DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL FULL-SERVICE OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL FULL-SERVICE OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL FULL-SERVICE OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL FUNCTIONAL OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL FUNCTIONAL OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL FUNCTIONAL OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL PROJECT-BASED ENGAGEMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL PROJECT-BASED ENGAGEMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PROJECT-BASED ENGAGEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL LONG-TERM STRATEGIC PARTNERSHIPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL LONG-TERM STRATEGIC PARTNERSHIPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL LONG-TERM STRATEGIC PARTNERSHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL INSOURCING SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL INSOURCING SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL INSOURCING SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ANIMAL MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL RODENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL RODENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL RODENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL RABBITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL RABBITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL RABBITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CANINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CANINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL SWINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL SWINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL SWINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL NON-HUMAN PRIMATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL NON-HUMAN PRIMATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL NON-HUMAN PRIMATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL DEVICE SAFETY ASSESSMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL DEVICE SAFETY ASSESSMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL DEVICE SAFETY ASSESSMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL EFFICACY & PERFORMANCE STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL EFFICACY & PERFORMANCE STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL EFFICACY & PERFORMANCE STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL PROTOTYPE VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL PROTOTYPE VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL PROTOTYPE VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL REGULATORY SUBMISSION SUPPORT (FDA/HC) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL REGULATORY SUBMISSION SUPPORT (FDA/HC) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL REGULATORY SUBMISSION SUPPORT (FDA/HC) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL MEDICAL DEVICE MANUFACTURERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL MEDICAL DEVICE MANUFACTURERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL MEDICAL DEVICE MANUFACTURERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL UNIVERSITIES & TEACHING HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL UNIVERSITIES & TEACHING HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL UNIVERSITIES & TEACHING HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL INDEPENDENT RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL INDEPENDENT RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL INDEPENDENT RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL GOVERNMENT & NONPROFIT ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL GOVERNMENT & NONPROFIT ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL GOVERNMENT & NONPROFIT ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL PUBLIC HEALTH AGENCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL PUBLIC HEALTH AGENCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL PUBLIC HEALTH AGENCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL STANDARDS & REGULATORY BODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL STANDARDS & REGULATORY BODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL STANDARDS & REGULATORY BODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL INVESTORS & STRATEGIC PARTNERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL INVESTORS & STRATEGIC PARTNERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL INVESTORS & STRATEGIC PARTNERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL VENTURE CAPITAL & PRIVATE EQUITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL VENTURE CAPITAL & PRIVATE EQUITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL VENTURE CAPITAL & PRIVATE EQUITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL STRATEGIC CORPORATE INVESTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL STRATEGIC CORPORATE INVESTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL STRATEGIC CORPORATE INVESTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VIVO TESTING, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO TESTING, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY BENCH & MECHANICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY & STERILITY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PACKAGING & SHELF-LIFE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SOFTWARE & DIGITAL HEALTH TESTING, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CHEMICAL CHARACTERIZATION SERVICES, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY NON IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ANIMAL MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY GOVERNMENT & NONPROFIT ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INVESTORS & STRATEGIC PARTNERS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VIVO TESTING, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO TESTING, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY BENCH & MECHANICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY & STERILITY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PACKAGING & SHELF-LIFE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SOFTWARE & DIGITAL HEALTH TESTING, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CHEMICAL CHARACTERIZATION SERVICES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY NON IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ANIMAL MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY GOVERNMENT & NONPROFIT ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INVESTORS & STRATEGIC PARTNERS, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VIVO TESTING, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO TESTING, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY BENCH & MECHANICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY & STERILITY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PACKAGING & SHELF-LIFE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 264. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SOFTWARE & DIGITAL HEALTH TESTING, 2018-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CHEMICAL CHARACTERIZATION SERVICES, 2018-2032 (USD MILLION)
  • TABLE 266. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 268. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY NON IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 270. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ANIMAL MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 274. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY GOVERNMENT & NONPROFIT ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 276. NORTH AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INVESTORS & STRATEGIC PARTNERS, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 278. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VIVO TESTING, 2018-2032 (USD MILLION)
  • TABLE 280. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO TESTING, 2018-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY BENCH & MECHANICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 282. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY & STERILITY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PACKAGING & SHELF-LIFE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 284. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SOFTWARE & DIGITAL HEALTH TESTING, 2018-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CHEMICAL CHARACTERIZATION SERVICES, 2018-2032 (USD MILLION)
  • TABLE 286. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 288. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY NON IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 290. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ANIMAL MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 294. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY GOVERNMENT & NONPROFIT ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 296. LATIN AMERICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INVESTORS & STRATEGIC PARTNERS, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VIVO TESTING, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO TESTING, 2018-2032 (USD MILLION)
  • TABLE 301. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY BENCH & MECHANICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 302. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY & STERILITY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 303. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PACKAGING & SHELF-LIFE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 304. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SOFTWARE & DIGITAL HEALTH TESTING, 2018-2032 (USD MILLION)
  • TABLE 305. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CHEMICAL CHARACTERIZATION SERVICES, 2018-2032 (USD MILLION)
  • TABLE 306. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 307. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 308. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY NON IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 309. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 310. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 311. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ANIMAL MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. AFRICA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY APPLICATION, 2